Previous 10 | Next 10 |
Gainers: Convey Health Solutions Holdings (CNVY) +139%. Valneva (VALN) +86%. Green Giant (GGE) +78%. CEA Industries (CEAD) +76%. Clovis Oncology (CLVS) +71%. Tabula Rasa HealthCare (TRHC) +34%. Revlon (REV) +34%. Innate Pharma (IPHA) +33%. Sorrento Therapeutics (SRNE) +28%. MacroGenics (MGNX)...
Fujian Blue Hat Interactive Entertainment Technology (BHAT) -45%. ACADIA Pharmaceuticals (ACAD) -33% as trading resumes after FDA snub for antipsychotic drug. Addex Therapeutics (ADXN) -11%. Kazia Therapeutics (KZIA) -7%. Gran Tierra Energy (GTE) -6%. PolarityTE (PTE) -6% ...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Addex Pharmaceuticals Terminates Dipraglurant Phase 2b/3 Study” Addex Therapeutics Ltd (NASDAQ: ADXN) , a clinical-stage pharmaceutical company pioneerin...
Gainers: Revlon (REV) +79%. Scholar Rock Holding (SRRK) +72%. SoundHound (SOUN) +25%. bluebird bio (BLUE) +25%. Q&K International Group (QK) +24%. Comera Life Sciences Holdings (CMRA) +22%. Momentus (MNTS) +22%. Clear Channel Outdoor Holdings (CCO) +21%. Centessa Pharmaceuticals (CNTA) +2...
Addex Therapeutics (ADXN) -36% after terminating lead program. ToughBuilt Industries (TBLT) -28%. Advent Technologies (ADN) -13%. Comera Life Sciences (CMRA) -9%. Sidus Space (SIDU) -8%. Aethlon Medical (AEMD) -8%. Rhythm Pharmaceuticals (RYTM) -4% after FDA rejects Rhythm...
The ADRs of Addex Therapeutics (NASDAQ:ADXN) crashed ~41% in the pre-market Friday after the Swiss biotech announced an end to its lead program of Phase 2b/3 study for experimental therapy dipraglurant in dyskinesia associated with Parkinson’s disease (PD-LID). The company at...
Addex Therapeutics (NASDAQ:ADXN) (OTC:ADDXF) said a phase 2a feasibility trial of dipraglurant in patients with blepharospasm was inconclusive and did not meet all of its goals. Blepharospasm is a rare neurological disorder affecting muscles around the eye which leads...
Addex Therapeutics press release (NASDAQ:ADXN): Q1 GAAP EPS of -CHF 0.15. Cash and cash equivalents amounted to CHF 14.9 million as of March 31, 2022, compared to CHF 25.2 million as of March 31, 2021, CHF 20.5 million as of December 31, 2021 and CHF 18.7 million as of December 31, 2020....
Addex Therapeutics (NASDAQ:ADXN) said it had moved a series of compounds called M4 muscarinic receptor positive allosteric modulator (PAM), that could potentially treat schizophrenia and other types of psychotic disorders, into lead program. "Research suggest that M4 PAMs coul...
Addex Therapeutics Limited (ADXN) Q4 2021 Earnings Conference Call March 10, 2022, 10:00 AM ET Company Participants Tim Dyer - CEO Roger Mills - Chief Medical Officer Robert Lutjens - Head of Discovery Biology Conference Call Participants Raghuram Selvaraju - HC Wainwright Bob Pooler - valuat...
News, Short Squeeze, Breakout and More Instantly...
Addex Therapeutics Ltd Company Name:
ADXN Stock Symbol:
NASDAQ Market:
Addex Therapeutics Ltd Website:
2024-07-19 15:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological...
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of T...